ImprimisRx to Assume Full Responsibility for US Sales and Marketing Activities for Dexycu
EyePoint Pharmaceuticals and ImprimisRx, a wholly owned subsidiary of Harrow Health, jointly announced the expansion of their commercial alliance in which ImprimisRx will assume responsibility for US sales and marketing activities for Dexycu (dexamethasone intraocular suspension) 9% for the treatment of postoperative inflammation following ocular surgery in the U.S. The amended agreement expands the commercial alliance previously established in August 2020 between the companies.
“EyePoint is excited to build upon our successful collaboration with ImprimisRx to promote awareness and demand for Dexycu to cataract surgeons and patients in need of more effective treatments to manage ocular inflammation following surgery,” Scott Jones, Chief Commercial Officer of EyePoint Pharmaceuticals, said in a company news release. “We are dedicated to providing long-lasting solutions to all patients suffering from ophthalmic diseases. This expanded partnership enables us to fully leverage ImprimisRx’s presence and tremendous expertise in ocular and cataract surgery, while allowing EyePoint to focus our efforts on advancing our retinal disease-focused pipeline. We look forward to working closely with the ImprimisRx team to accelerate Dexycu's growth, bringing its many benefits to more physicians and patients.”
Under the terms of the deal, ImprimisRx will assume responsibility for the sales and marketing of Dexycu in the U.S. and will absorb the majority of EyePoint’s Dexycu commercial organization. EyePoint will continue to recognize net product revenue and maintain manufacturing and distribution responsibilities for Dexycu along with non-sales related regulatory compliance. EyePoint will pay ImprimisRx a commission based on the net sales of Dexycu and will retain all commercial rights for Dexycu. This amended agreement will be effective on January 1, 2022.
“We are pleased to expand our partnership with EyePoint to continue to bring Dexycu, an innovative FDA-approved injectable steroid product, to patients experiencinginflammation following ocular surgery,” said John Saharek, President of ImprimisRx. “A growing number of our ophthalmologist customers experience the benefits Dexycu offers as a sustained release treatment option that is a complement to their patients’ eye drop regimen. We are pleased with the success we have had thus far in building customer demand for Dexycu, which we expect to grow as result of the expansion of our partnership with EyePoint. We look forward to executing our U.S. commercial strategy alongside EyePoint to attain our shared goal of even greater success for many years to come.”